Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-06-12
2011-10-11
Navarro, Albert (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S190100, C424S234100, C424S250100, C514S04400A, C530S300000, C530S350000, C536S023700
Reexamination Certificate
active
08034349
ABSTRACT:
Peptides that mimic the antigenic features of non human-cross-reactive protective epitopes of the MenB CP and nucleic acids encoding the peptide mimetics are disclosed. Antibodies elicited by these peptides do not bind to polysialic acid in host tissue and thus provide a safe and efficacious method for the treatment and/or prevention of Meningitis B.
REFERENCES:
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4727136 (1988-02-01), Jennings et al.
patent: 4970070 (1990-11-01), Raff
patent: 5576002 (1996-11-01), Jennings et al.
patent: 5683699 (1997-11-01), Jennings et al.
patent: 5811102 (1998-09-01), Jennings et al.
patent: 5902586 (1999-05-01), Jennings et al.
patent: 5969130 (1999-10-01), Jennings et al.
patent: 6030619 (2000-02-01), Granoff et al.
patent: 6048527 (2000-04-01), Granoff et al.
patent: 6638513 (2003-10-01), Seid
patent: 7534444 (2009-05-01), Granoff et al.
patent: 2004/0034888 (2004-02-01), Liu et al.
patent: 0145359 (1985-06-01), None
patent: 0504202 (1995-05-01), None
patent: 1708846 (1992-01-01), None
patent: WO-90/06696 (1990-06-01), None
patent: WO-91/06772 (1991-06-01), None
patent: WO-95/14085 (1995-05-01), None
patent: WO-98/05543 (1998-03-01), None
patent: WO-2007/073706 (2007-07-01), None
patent: WO 2007/073706 (2007-07-01), None
Moe, G. et al. “Molecular mimetics of polysaccharide epitopes as vaccines candidates for prevention ofNeisseria meningitidisserogroup B disease,” FEMS, 26: 209-226 (1999).
Granoff, D. et al. “Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do . . . ” Journal of Immunology, 160 (10):5028-5036 (1998).
Shin, J. et al. “Monoclonal antibodies specific forNeisseria meningitidisgroup B polysaccharide and their peptide mimotopes,” Infect. Immun., 69 (5): 3335-3342 (2001).
Passo, C. et al. “Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after . . . ” Journal of Immunology, 178 (7): 4417-4423 (2007).
Ashton et al., “Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide,”Microb. Patheogeneis6:455-458 (1989).
Ashton et al., “Immunological properties of monoclonal antibodies to the N-propionyl derivative of group B meningococcal polysaccharide,”In: Neisseria 1990, Achtman M.(Ed.),Walter De Gruyter&Co.Berlin pp. 187-191 (1991).
Bartoloni et al., “Immunogenicity of meningococcal B polysaccharide conjugated to tetanus tosoid or CRM197 via adipic acid dihydrazide,”Vaccine13(5):463-470 (1995).
Baumann et al., “Comparison of the conformation of the epitope of alpha(2á8) polysialic acid with its reduced and N-acyl derivatives,”Biochemistry32:4007-4013 (1993).
Bitter-Suermann et al., “Monoclonal antibodies to polysialic acid reveal epitope sharing between invasive pathogenic bacteria, differentiating cells and tumor cells,”Immunol. Res.6(4):225-237 (1987).
Bowie et al., “Deciphering the message in protein sequences: Tolerance to amino acid substitutions,”Science247:1306-1310 (1990).
Brisson et al., “Helical Epitope of the Group B Meningococcal a92-B)-Linked Sialic Acid Polysaccharide,”Biochemistry31(21):4996-5004 (1992).
Burgess et al., (1990). “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”J. Cell Biol.111:2129-2138.
Cross et al., “Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positiveEscherichia coli,” J. Infect. Dis.147(1):68-76 (1983).
Devi et al., “Binding diversity of monoclonal antibodies to alpha(2-8) polysialic acid conjugated to outer membrane vesicle via adipic acid dihydrazide,”FEMS Immunol. Med. Microbiol.11.:211-220 (1996).
Devi et al, (Mar. 1997). “Preclinical evaluation of group BNeisseria meningitidisandEscherichia coliK92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys,” Infect Immun 65(3):1045-52.
Dubois et al., “A Monoclonal Antibody AgainstMeningococcusGroup B Polysaccharides Used to Immunocapture and Quantify Polysialylated NCAM in Tissues and Biological Fluids,”Journal of Immunological Methods181:125-135 (1995).
Frasch, Carl E., “Meningococcal Vaccines: Past, Present and Future,”Meningococcal Disease245-283 (1995).
Frosch et al., “NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: Isolation of an IgG antibody to the polysaccharide capsules ofEscherichia coliK1 and group B meningococci,”PNAS82: 1194-1198 (1985).
Fusco et al., “Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in Both Mice and Nonhuman Primates,”The Journal of Infectious Disease175:364-372 (1997).
Granoff et al., “Antibody Responses to the Capsular Polysaccharide ofNeisseria menignitidisSerogroup B in Patients With Meningococcal Disease,”Clinical and Diagnostic Laboratory Immunology2(5):574-582 (1995).
Gregson et al., “Monoclonal antibodies against meningococcal polysaccharide with cross-reactivity against brain antigens,”Biochem. Soc. Transact.13;p. 462 (1985).
Hayrinen et al., “Antibodies to Polysialic Acid and its N-Propyl Derivative: Binding Properties and Interaction with Human Embryonal Brain Glycopeptides,”The Journal Of Infectious Diseases171 :1481-1490 (1995).
Horwell, David C. “The ‘Peptoid’ Approach to the Design of Non-Peptide, Small Molecule Agonist and Antagonists of Neuropeptides,”TIBTech13(4): 132-134 (1995).
Hurpin et al., “Bactericidal activity of two Ig2a murine monoclonal antibodies with disilnet fine specificities for group BNeisseria meningitidiscapsular polysaccharide,”Hybridoma11(6):677-687 (1992).
Husmann et al., “Immunohistochemical localization of polysialic acid in tissue sections: differential binding to polynucleolides and DNA of a murine IgG and a human IgM monoclonal antibody,”J. Histochem Cytochem.38:209-215 (1990).
Jennings. Harold J., “The Capsular Polysaccharide of Group BNeisseria meningitidisas a Vehicle for Vaccine Development,”Microbiol. Immunol.10:151-165 (1989).
Jennings et al., “Induction ofMeningococcalGroup B Polysaccharide-Specific IgG Antibodies in Mice by Using an N-Propionylated B Polysaccharide-Tetanus Toxoid Conjugate Vaccine,”The J. of Immunology137(5):1708-1713 (1986).
Jennings et al., “N-Polysialic Group B Meningococcal Polysaccharide Mimic a Unique Epitope on Group BNeisseria meningitidis,” J. Experimental Medicine165: 1207-1211 (1987).
Jennings et al. “Unique Intermolecular Bactericidal Epitope Involving the Homosialopolysaccharide Capsule on the Cell Surface of Group BNeisseria meningitidisandEscherichia coliK1,”Journal of Immunology142(10):3585-3591 (1989).
Jennings et al., “Immunochemistry of Groups A,B, and C Meningococcal Polysaccharide-Tetanus Toxoid Cojugates,”The Journal of Immunology127(3):1011-1018 (1981).
Kabat et al., “A human monoclonal macroglobulin with specificity of alpha(2→8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci andEschericia coliK1, which crossreacts with polynucleotides and with denatured DNA,”J. Exp. Med.164:642-654 (1986).
Klebert et al., “Primary structure of the murine monoclonal IgG2a antibody mAb735 against alpha (2-8) polysialic acid. 2. Amino acid sequence of the heavy (H−) chain Fd′ region,”Biol. Chem. Hoppe Seyler374:993-1000 (1993).
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Mol. Cell Biol.8:1247-1252, 1988.
Leinonen et al., “
Felici Franco
Teti Giuseppe
Felici Franco
Gorman Robert
Hessler Amy
Littlefield Otis
Navarro Albert
LandOfFree
Peptides that mimic non-human cross-reactive protective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides that mimic non-human cross-reactive protective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides that mimic non-human cross-reactive protective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284468